Patent SG-11201906525S-A (SG)
Title: Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
Inventor: CHENG YUAN
IPC: A61P3/10
Filed: 2018-01-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT o mono °nolo Ho Ho lio imio oimIE (10) International Publication Number WO 2018/136440 Al (51) International Patent Classification: A61K 39/395 (2006.01) A61P 3/10 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2018/013918 (22) International Filing Date: 16 January 2018 (16.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/447,332 17 January 2017 (17.01.2017) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320 (US). (72) Inventors: CHENG, Yuan; 5329 Via Jacinto, New- bury Park, California 91320 (US). NETIROJJANAKUL, Chawita; 4631 Kester Ave., Apt. 103, Sherman Oaks, Cali- fornia 91403 (US). HOLDER, Jerry Ryan; 1102 Waltham Road, Simi Valley, California 93065 (US). WU, Bin; 3090 Hollycrest Avenue, Thousand Oaks, California 91362 (US). FALSEY, James R.; 13209 Peach Hill Road, Moor- park, California 93021 (US). HERBERICH, Bradley J.; 1746 Hays Drive, Newbury Park, California 91320 (US). SHAM, Kelvin; 3111 La Casa Court, Thousand Oaks, Cal- ifornia 91362 (US). MIRANDA, Leslie P.; 3586 Maple- knoll Place, Thousand Oaks, California 91362 (US). LU, Shu-Chen; 2356 Rutland Place, Thousand Oaks, Califor- nia 91362 (US). VENIANT-ELLISON, Murielle M.; 645 Camino Manzanas, Thousand Oaks, California 91360 (US). STANISLAUS, Shanaka; 4196 Minnecota Drive, Thou- sand Oaks, California 91360 (US). YIE, Junming; 4 Sugar- wood Way, Warren, New Jersey 07059 (US). XU, Jing; 67 Bishops Forest Drive, Waltham, Massachusetts 02452 (US). (74) Agent: DERMOTT, Jonathan M. et al.; One Amgen Cen- ter Drive, Patent Operations, MS-35-1-B, Thousand Oaks, California 91320 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) W O 20 18/ 136 440 Al (54) Title: METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) (57) : Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.